Thursday, August 18, 2016
Rockwell Medical enters into exclusive license agreement with ARAM Medical to commercialize Triferic in Saudi Arabia, Egypt and Middle East territories.
ARAM will also assume responsibility for all clinical and regulatory expenses for territories.
Rockwell retains manufacturing responsibilities for both Triferic and Calcitriol.
Commercial product availability expected within about 12 months in Saudi Arabia and 12 to 18 months in Egypt and all other territories.
ARAM medical will become exclusive distributor for Triferic and Calcitriol in 13 countries.
ARAM will pay to Rockwell upfront licensing fees, a "high double-digit royalty on product sales".
Source : reuters.com
